| Molecular formula | C27H36N4O5S |
|---|
| Molecular weight | 528.7 g/mol |
|---|
| Registered trials | 8 |
|---|
| PubChem CID | 178024 |
|---|
Ibutamoren, also known by its research code MK-0677, is a compound studied for its effects on growth hormone secretion, but it does not carry an FDA-approved label. Anyone encountering it in a research or supplement context should understand that its regulatory footing is investigational rather than approved.
What ibutamoren is
Ibutamoren is a small molecule identified in chemical databases under PubChem CID 178024. It has been studied as an orally administered growth hormone secretagogue, meaning it is investigated for its ability to prompt the body to release growth hormone. No FDA-approved drug label currently exists for this compound, so there are no approved indications, approved brand names, or label-defined mechanism of action to report.
Clinical trial footprint
Eight clinical trials involving ibutamoren are registered. Among the studied trials, one Phase 2 study, "The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease," has been completed. Another Phase 2 trial, "Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia," also reached completed status. A further study examined the compound's effect on IGF-1 levels in patients with end-stage renal disease. These trials reflect the range of conditions researchers have investigated, not established or approved uses.
FAQ
No. Ibutamoren does not have an FDA-approved drug label, and there are no approved indications or brand names associated with it. It remains an investigational compound studied in clinical research settings.
Clinical trials have examined ibutamoren in contexts such as nonalcoholic fatty liver disease, fibromyalgia, and IGF-1 levels in patients with end-stage renal disease. These studies are research investigations and do not establish approved uses or confirmed benefits.
There are 8 registered clinical trials involving ibutamoren. The available sample includes completed Phase 2 studies as well as a study without an assigned phase.
Yes. MK-0677 is the research code used for ibutamoren in scientific literature and clinical trial listings, including studies on growth hormone secretion.
No adverse event report data was available for this compound at the time of review. Anyone considering its use should be aware that its safety profile has not been established through an approved label.
This page is an editorial information resource. It does not sell, prescribe, or recommend any medication.
Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.
Sources: PubChem CID 178024 ClinicalTrials.gov
Updated 2026-09-26